In this article, we will discuss Ramucirumab (17). So, let’s get started.
Impaired Wound Healing
Ramucirumab has not been studied in patients with serious or non-healing wounds. Ramucirumab is an antiangiogenic therapy with the potential to adversely affect wound healing. Withhold Ramucirumab prior to surgery. Resume following the surgical intervention based on clinical judgment of adequate wound healing. If a patient develops wound healing complications during therapy, discontinue CYRAMZA until the wound is fully healed.